Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Stryker Corporation — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $93.3, while Stryker Corporation trades at $319.04 (market cap $122.35B). The key difference: Stryker Corporation pays a 1% dividend while iShares 7-10 Year Treasury Bond ETF pays none, and Stryker Corporation is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEF | SYK | |
|---|---|---|
52-Week High | $97.99 | $403.53 |
52-Week Low | $93.11 | $282.58 |
Market Cap | — | $122.35B |
Sector | — | Technology |
Enterprise Value | — | $134.10B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF trades at $93.31, down 0.56% on the day amid a bearish technical outlook with moving averages signaling sell pressure. Recent dividends of $0.31-$0.32 per share reflect income stability, while news highlights bond ETF competition and Federal Reserve uncertainty. The asset faces headwinds from rising rate hike expectations and inflation concerns, with technical indicators showing neutral oscillators but bearish trend strength.
The outlook for IEF remains cautious due to potential Fed tightening and bond market volatility. Investment appeal hinges on income generation from dividends, but risks include interest rate sensitivity and macroeconomic shifts. Investors should weigh yield advantages against duration risk in a fluctuating rate environment.
Stryker (SYK) trades at $319.14, down 0.23% with a bearish technical signal despite strong fundamentals. The company reported $25.12B revenue and $3.25B net income for 2025, maintaining robust margins. Recent news highlights Mako RPS launch expansion in robotic surgery, while Q1 2026 earnings missed expectations due to a temporary cyber disruption, though full-year guidance remains unchanged.
Outlook remains positive with 74% analyst buy ratings and a $388.44 consensus price target implying 22% upside. Key risks include competitive pressures and execution challenges from recent cybersecurity issues. The stock presents a growth opportunity in med-tech innovation, trading below historical valuation multiples with healthy cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
